Wells Fargo lowers Amphastar Pharmaceuticals [AMPH] rating to Equal-Weight and sets price target at $21
Wells Fargo took its Amphastar Pharmaceuticals [AMPH] rating to the equivalent of Equal-Weight from Overweight, and the price target to $21.0, in a research note dated 2021-01-08. That figure represents around a 1.69% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Northland Capital’s analysts upgrading the shares […]
Euronav [EURN] gets an upgrade to a Buy from BTIG
BTIG took its Euronav [EURN] rating to the equivalent of Buy from Neutral, in a research note dated 2021-01-08. Other analysts also revised their coverage, with BTIG Research’s analysts downgrading the shares from “a Buy” rating to “a Neutral” rating in a research note to investors issued in late October. Meanwhile, DNB Markets had raised […]
Evercore ISI Group upgrades Principal Financial Group to Outperform and price target to $60
Evercore ISI Group took its Principal Financial Group [PFG] rating to the equivalent of Outperform from In-line, and the price target to $60.0 from $49, in a research note dated 2021-01-08. That figure represents around a 15.96% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Goldman’s analysts […]
BMO Capital upgrades Sabra Health Care REIT to Market Perform and price target to $19
BMO Capital took its Sabra Health Care REIT [SBRA] rating to the equivalent of Market Perform from Underperform, and the price target to $19.0, in a research note dated 2021-01-08. That figure represents around a 11.6% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with JMP Securities’s analysts […]
Needham maintains Revance Therapeutics [RVNC] at Buy rating with a $45 price target
Needham maintained its Revance Therapeutics [RVNC] rating to the equivalent of Buy but changed the price target to $45.0 from $42, in a research note dated 2021-01-08. That figure represents around a 52.08% premium from where the company’s shares closed on Thursday. Meanwhile, Goldman had lowered its rating on RVNC to “Neutral” from the earlier […]
Insider Selling: iRhythm Technologies Inc. [IRTC] EVP, Sales Sells 5,000 Shares Worth $1,140,431
On Jan. 05, Vort David A divested U.S. $1,140,431 in shares of iRhythm Technologies Inc.. The EVP, Sales sold 5,000 shares at a price per share of $228.09. The transaction decreased this specific insider’s holdings to 15,602 shares worth around $3.43 million at present. Oppenheimer took its iRhythm Technologies Inc. [IRTC] rating to the equivalent […]
PennyMac Financial Services Inc. [PFSI] Insider Just Sold 31,000 Shares. Should You?
On Jan. 05, Kurland Stanford L divested U.S. $1,863,773 in shares of PennyMac Financial Services Inc.. The Dir, 10% sold 31,000 shares at a price per share of $60.12. The transaction decreased this specific insider’s holdings to 7,718,813 shares worth around $451.01 million at present. Jefferies launched its PennyMac Financial Services Inc. [PFSI] rating to […]
SQZ Biotechnologies [SQZ] gets fresh Outperform rating from Evercore ISI Group
Evercore ISI Group launched its SQZ Biotechnologies [SQZ] rating to the equivalent of Outperform and assigned the price target of $nan, in a research note dated 2021-01-08. That figure represents around a nan% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with BTIG Research’s analysts assigning the […]
Newstead Jennifer Has Sold $83,204 in Facebook Inc. [FB] Stock
On Jan. 05, Newstead Jennifer divested U.S. $83,204 in shares of Facebook Inc.. The VP, GC sold 310 shares at a price per share of $268.40. The transaction decreased this specific insider’s holdings to 1,572 shares worth around $0.42 million at present. Meanwhile, Monness Crespi & Hardt had maintained its rating on FB to the […]
SVB Leerink reiterates Sarepta Therapeutics [SRPT] rating to Outperform and sets new price target at $125
SVB Leerink maintained its Sarepta Therapeutics [SRPT] rating to the equivalent of Outperform but changed the price target to $125.0 from $197, in a research note dated 2021-01-08. That figure represents around a -26.01% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with UBS’s analysts assigning the […]
